Cervical screening during the COVID-19 pandemic: optimising recovery strategies
- PMID: 33939965
- PMCID: PMC8087290
- DOI: 10.1016/S2468-2667(21)00078-5
Cervical screening during the COVID-19 pandemic: optimising recovery strategies
Abstract
Disruptions to cancer screening services have been experienced in most settings as a consequence of the COVID-19 pandemic. Ideally, programmes would resolve backlogs by temporarily expanding capacity; however, in practice, this is often not possible. We aim to inform the deliberations of decision makers in high-income settings regarding their cervical cancer screening policy response. We caution against performance measures that rely solely on restoring testing volumes to pre-pandemic levels because they will be less effective at mitigating excess cancer diagnoses than will targeted measures. These measures might exacerbate pre-existing inequalities in accessing cervical screening by disregarding the risk profile of the individuals attending. Modelling of cervical screening outcomes before and during the pandemic supports risk-based strategies as the most effective way for screening services to recover. The degree to which screening is organised will determine the feasibility of deploying some risk-based strategies, but implementation of age-based risk stratification should be universally feasible.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests MR reports funding from Hologic and grants from Public Health England, outside of the submitted work. MAS reports grants from the National Health and Medical Research Council and the Cancer Institute New South Wales. SJBH reports grants from National Cancer Centre Japan. SP reports being a member of the Board of Directors for the Canadian Agency for Drugs and Technologies in Health. All other authors declare no competing interests.
References
-
- Vose JM. Delay in cancer screening and diagnosis during the COVID-19 pandemic: what is the cost? Oncology (Williston Park) 2020;34:343. - PubMed
Uncited References
-
- Public Health England. Department of Health & Social Care Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 2021. https://www.gov.uk/government/publications/guidance-on-shielding-and-pro...
